Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cibotercept by Keros Therapeutics for Pulmonary Arterial Hypertension: Likelihood of Approval
Cibotercept is under clinical development by Keros Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension. According to GlobalData,...
KER-065 by Keros Therapeutics for Obesity: Likelihood of Approval
KER-065 is under clinical development by Keros Therapeutics and currently in Phase I for Obesity. According to GlobalData, Phase I...
KER-065 by Keros Therapeutics for Duchenne Muscular Dystrophy: Likelihood of Approval
KER-065 is under clinical development by Keros Therapeutics and currently in Phase I for Duchenne Muscular Dystrophy. According to GlobalData,...
Elritercept by Keros Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
Elritercept is under clinical development by Keros Therapeutics and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...
Elritercept by Keros Therapeutics for Anemia: Likelihood of Approval
Elritercept is under clinical development by Keros Therapeutics and currently in Phase II for Anemia. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Keros Therapeutics's Elritercept?
Elritercept is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Anemia. According to Globaldata,...